What is Zolmitriptan?

Zolmitriptan is used to treat the symptoms of migraine headaches .

Zolmitriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels around the brain, stopping pain signals from being sent to the brain.

Zolmitriptan does not prevent migraine attacks or reduce the number of headaches .

In clinical studies with Zolmitriptan conventional tablets the onset of efficacy is apparent from one hour.

Zolmitriptan is rapidly and well absorbed (at least 64%) after oral administration to man.

The mean absolute bioavailability of the parent compound is approximately 40%.

There is an active metabolite (the N-desmethyl metabolite) which is also a 5HT 1B/1D receptor agonist and is 2 to 6 times as potent, in animal models, as Zolmitriptan.


In healthy volunteers, 75% of Cmax is achieved within 1 hour, and after this the concentration of Zolmitriptan in plasma is maintained at approximately this level until 4-5 hours after dosing.

Zolmitriptan absorption is unaffected by the presence of food. There was no evidence of accumulation on multiple dosing of Zolmitriptan.

Zolmitriptan is eliminated largely by hepatic biotransformation followed by urinary excretion of the metabolites.

Over 60% of a single oral dose is excreted in the urine and about 30% in faeces mainly as unchanged parent compound.


Zolmigo- Special Populations

Children (below 12 years of age)

Safety and efficacy of zolmitriptan tablets in paediatric patients have not been evaluated. Use of zolmitriptan in children is therefore not recommended.

Use in patients aged over 65 years

The safety and efficacy of zolmitriptan in individuals aged over 65 years have not been evaluated. Use of zolmitriptan in older people is therefore not recommended.

Patients with hepatic impairment

Patients with mild or moderate hepatic impairment require no dose adjustment, however for patients with severe hepatic impairment, a maximum dose of 5 mg in 24 hours is recommended.

Patients with renal impairment

No dosage adjustment required in patients with a creatinine clearance of more than 15 ml/min

Adolescents (12 - 17 years of age)

The efficacy of zolmitriptan tablets was not demonstrated in a placebo controlled clinical trial for patients aged 12 to 17 years. Use of zolmitriptan in adolescents is therefore not recommended

Pregnancy , Lactation

Not recommended.


Drug Interactions

Ergotamines :the increased risk of coronary vasospasm is a theoretical possibility, and concomitant administration is contraindicated.

Other Triptans .

A maximum dose of 5 mg zolmitriptan in 24 hours is recommended in patients taking cimetidine.



Moderate or severe hypertension, and mild uncontrolled hypertension.

Myocardial infarction , ischaemic heart disease ,transient ischaemic attack, or coronary vasospasm.

Hypersensitivity to the active substance.


Kinds of Headaches




Rapid and effective relief of migraine attack within one hour.

Should be given early in the course of the attack.

Zolmigo absorption is unaffected by the presence of food.

No accumulation on multiple dosing.

No dosage adjustment required in patients with mild or moderate hepatic or renal impairment.

Cost effective treatment of migraine.